Coagulation

Source: Wikipedia, the free encyclopedia.
(Redirected from
Fibrin generation
)

Coagulation
Blood coagulation pathways in vivo showing the central role played by thrombin
HealthBeneficial

Coagulation, also known as clotting, is the process by which blood changes from a liquid to a gel, forming a blood clot. It potentially results in hemostasis, the cessation of blood loss from a damaged vessel, followed by repair. The mechanism of coagulation involves activation, adhesion and aggregation of platelets, as well as deposition and maturation of fibrin.

Coagulation begins almost instantly after an injury to the

factor VII, which ultimately leads to cross-linked fibrin formation. Platelets immediately form a plug at the site of injury; this is called primary hemostasis. Secondary hemostasis occurs simultaneously: additional coagulation (clotting) factors beyond factor VII (listed below) respond in a cascade to form fibrin strands, which strengthen the platelet plug.[1]

Disorders of coagulation are disease states which can result in problems with hemorrhage, bruising, or thrombosis.[2]

Coagulation is highly conserved throughout biology. In all mammals, coagulation involves both cellular components (platelets) and proteinaceous components (here, coagulation factors).[3] The pathway in humans has been the most extensively researched and is the best understood.[4]

List of coagulation factors

There are 12 traditional clotting factors, as named below,[5] and other substances necessary for coagulation:

Coagulation factors and related substances
Number/Name Synonym(s) Function Associated genetic disorders Type of molecule Source Pathway(s)
Factor I Fibrinogen Forms fibrin threads in blood clots Plasma protein Liver Common pathway; converted into fibrin
Factor II* Prothrombin Its active form (IIa) activates platelets, factors I, V, VII, VIII, XI, XIII, protein C
  • Prothrombin thrombophilia (Prothrombin G20210A)[6]
Plasma protein Liver Common pathway; converted into thrombin
Factor III
  • Tissue factor
  • tissue thromboplastin
Co-factor of factor VIIa, which was formerly known as factor III Lipoprotein mixture Damaged cells and platelets Extrinsic
Factor IV
  • Calcium
  • Calcium ions
  • Ca2+ ions
Required for coagulation factors to bind to phospholipids, which were formerly known as factor IV Inorganic ions in plasma Diet, platelets, bone matrix Entire process of coagulation
Factor V
  • Proaccelerin
  • labile factor
  • Ac-globulin
Co-factor of factor X with which it forms the prothrombinase complex Activated protein C resistance Plasma protein Liver, platelets Extrinsic and intrinsic
Factor VI
  • Unassigned
    old name of factor Va
    (activated form of factor V)
  • accelerin (formerly)
N/A N/A N/A
Factor VII
*
  • Proconvertin
  • Serum Prothrombin Conversion Accelerator (SPCA)
  • Stable factor
Activates factors IX, X; increases rate of catalytic conversion of prothrombin into thrombin Congenital factor VII deficiency Plasma protein Liver Extrinsic
Factor VIII
  • Antihemophilic factor A
  • Antihemophilic factor (AHF)
  • Antihemophilic globulin (AHG)
Co-factor of factor IX with which it forms the tenase complex
Hemophilia A
Plasma protein factor Platelets and endothelial cells Intrinsic
Factor IX*
  • Antihemophilic factor B
  • Christmas factor
  • plasma thromboplastin component (PTC)
Activates factor X, forms tenase complex with factor VIII
Hemophilia B
Plasma protein Liver Intrinsic
Factor X*
  • Stuart-Prower factor
  • Stuart factor
Activates factor II, forms prothrombinase complex with factor V Congenital Factor X deficiency Protein Liver Extrinsic and intrinsic
Factor XI
  • Plasma thromboplastin antecedent (PTA)
  • Antihemophilic factor C
Activates factor IX
Hemophilia C
Plasma protein Liver Intrinsic
Factor XII Hageman factor Activates XI, VII, prekallikrein and plasminogen Hereditary angioedema type III Plasma protein Liver Intrinsic; initiates clotting in vitro; also activates plasmin
Factor XIII Fibrin-stabilizing factor Crosslinks fibrin threads Congenital factor XIIIa/b deficiency Plasma protein Liver, platelets Common pathway; stabilizes fibrin; slows down fibrinolysis
Vitamin K Clotting vitamin Essential factor to the hepatic
carboxyl group to glutamic acid residues on factors II, VII, IX and X, as well as Protein S, Protein C and Protein Z[7]
Vitamin K deficiency Phytyl-substituted naphthoquinone derivative Gut microbiota
(e.g. E. coli[8]),
dietary sources
Extrinsic[9]
von Willebrand factor Binds to VIII, mediates platelet adhesion von Willebrand disease Blood glycoprotein Blood vessels'
endothelia,
bone marrow[10]
Prekallikrein Fletcher factor Activates XII and prekallikrein; cleaves HMWK Prekallikrein/Fletcher factor deficiency
Kallikrein Activates plasminogen
High-molecular-weight kininogen
  • Fitzgerald factor
  • HMWK
Supports reciprocal activation of factors XII, XI, and prekallikrein Kininogen deficiency
Fibronectin Mediates cell adhesion Glomerulopathy with fibronectin deposits
Antithrombin III Inhibits factors IIa, Xa, IXa, XIa, and XIIa Antithrombin III deficiency
Heparin cofactor II Inhibits factor IIa, cofactor for heparin and dermatan sulfate ("minor antithrombin") Heparin cofactor II deficiency
Protein C Inactivates factors Va and VIIIa Protein C deficiency
Protein S Cofactor for activated protein C (APC, inactive when bound to C4b-binding protein Protein S deficiency
Protein Z Mediates thrombin adhesion to phospholipids and stimulates degradation of factor X by ZPI Protein Z deficiency
Protein Z-related protease inhibitor ZPI Degrades factors X (in presence of protein Z) and XI (independently
Plasminogen
Converts to plasmin, lyses fibrin and other proteins Plasminogen deficiency type I (ligneous conjunctivitis)
α2-Antiplasmin Inhibits plasmin Antiplasmin deficiency
α2-Macroglobulin Inhibits plasmin, kallikrein, and thrombin
Tissue plasminogen activator
t-PA or TPA Activates plasminogen
Urokinase Activates plasminogen Quebec platelet disorder
Plasminogen activator inhibitor-1 PAI-1 Inactivates tPA and urokinase (endothelial PAI Plasminogen activator inhibitor-1 deficiency
Plasminogen activator inhibitor-2 PAI-2 Inactivates tPA and urokinase Plasminogen activator inhibitor-1 deficiency
Cancer procoagulant Pathological activator of factor X; linked to thrombosis in various cancers[11]
* Vitamin K is required for biosynthesis of these clotting factors[7]

Physiology

The interaction of vWF and GP1b alpha. The GP1b receptor on the surface of platelets allows the platelet to bind to vWF, which is exposed upon damage to vasculature. The vWF A1 domain (yellow) interacts with the extracellular domain of GP1ba (blue).

Physiology of blood coagulation is based on hemostasis, the normal bodily process that stops bleeding. Coagulation is a part of an integrated series of haemostatic reactions, involving plasma, platelet, and vascular components.[12]

Hemostasis consists of four main stages:

After the fibrin clot is formed,

plasminogen into plasmin, which promotes lysis of the fibrin clot; this restores the flow of blood in the damaged/obstructed blood vessels.[21]

Vasoconstriction

When there is an injury to a blood vessel, the endothelial cells can release various vasoconstrictor substances, such as endothelin[22] and thromboxane,[23] to induce the constriction of the smooth muscles in the vessel wall. This helps reduce blood flow to the site of injury and limits bleeding.

Platelet activation and platelet plug formation

When the endothelium is damaged, the normally isolated underlying collagen is exposed to circulating platelets, which bind directly to collagen with collagen-specific

glycoprotein VI triggers a signaling cascade that results in activation of platelet integrins. Activated integrins mediate tight binding of platelets to the extracellular matrix. This process adheres platelets to the site of injury.[24]

Activated platelets release the contents of stored granules into the blood plasma. The granules include ADP, serotonin, platelet-activating factor (PAF), vWF, platelet factor 4, and thromboxane A2 (TXA2), which, in turn, activate additional platelets. The granules' contents activate a Gq-linked protein receptor cascade, resulting in increased calcium concentration in the platelets' cytosol. The calcium activates protein kinase C, which, in turn, activates phospholipase A2 (PLA2). PLA2 then modifies the integrin membrane glycoprotein IIb/IIIa, increasing its affinity to bind fibrinogen. The activated platelets change shape from spherical to stellate, and the fibrinogen cross-links with glycoprotein IIb/IIIa aid in aggregation of adjacent platelets, forming a platelet plug and thereby completing primary hemostasis).[25]

Coagulation cascade

The classical blood coagulation pathway[26]
Modern coagulation pathway. Hand-drawn composite from similar drawings presented by Professor Dzung Le, MD, PhD, at UCSD Clinical Chemistry conferences on 14 and 21 October 2014. Original schema from Introduction to Hematology by Samuel I. Rapaport. 2nd ed.; Lippencott: 1987. Dr Le added the factor XI portion based on a paper from about year 2000. Dr. Le's similar drawings presented the development of this cascade over 6 frames, like a comic.

The coagulation cascade of secondary hemostasis has two initial pathways which lead to

Roman numerals, with a lowercase a appended to indicate an active form.[26]

The coagulation factors are generally

zymogens
. The coagulation cascade is therefore classically divided into three pathways. The tissue factor and contact activation pathways both activate the "final common pathway" of factor X, thrombin and fibrin.
[28]

Tissue factor pathway (extrinsic)

The main role of the tissue factor (TF) pathway is to generate a "thrombin burst", a process by which thrombin, the most important constituent of the coagulation cascade in terms of its feedback activation roles, is released very rapidly. FVIIa circulates in a higher amount than any other activated coagulation factor. The process includes the following steps:[26]

  1. Following damage to the blood vessel, FVII leaves the circulation and comes into contact with tissue factor expressed on tissue-factor-bearing cells (stromal fibroblasts and leukocytes), forming an activated complex (TF-FVIIa).
  2. TF-FVIIa activates FIX and FX.
  3. FVII is itself activated by thrombin, FXIa, FXII, and FXa.
  4. The activation of FX (to form FXa) by TF-FVIIa is almost immediately inhibited by tissue factor pathway inhibitor (TFPI).
  5. FXa and its co-factor FVa form the
    prothrombin
    to thrombin.
  6. Thrombin then activates other components of the coagulation cascade, including FV and FVIII (which forms a complex with FIX), and activates and releases FVIII from being bound to vWF.
  7. FVIIIa is the co-factor of FIXa, and together they form the "tenase" complex, which activates FX; and so the cycle continues. ("Tenase" is a contraction of "ten" and the suffix "-ase" used for enzymes.)

Contact activation pathway (intrinsic)

The

FXII (Hageman factor). Prekallikrein is converted to kallikrein and FXII becomes FXIIa. FXIIa converts FXI into FXIa. Factor XIa activates FIX, which with its co-factor FVIIIa form the tenase complex, which activates FX to FXa. The minor role that the contact activation pathway has in initiating blood clot formation can be illustrated by the fact that individuals with severe deficiencies of FXII, HMWK, and prekallikrein do not have a bleeding disorder. Instead, contact activation system seems to be more involved in inflammation,[26] and innate immunity.[29] Despite this, interference with the pathway may confer protection against thrombosis without a significant bleeding risk.[29]

Final common pathway

The division of coagulation in two pathways is arbitrary, originating from laboratory tests in which clotting times were measured either after the clotting was initiated by glass, the intrinsic pathway; or clotting was initiated by thromboplastin (a mix of tissue factor and phospholipids), the extrinsic pathway.[citation needed]

Further, the final common pathway scheme implies that prothrombin is converted to thrombin only when acted upon by the intrinsic or extrinsic pathways, which is an oversimplification. In fact, thrombin is generated by activated platelets at the initiation of the platelet plug, which in turn promotes more platelet activation.[citation needed]

Thrombin functions not only to convert fibrinogen to fibrin, it also activates Factors VIII and V and their inhibitor protein C (in the presence of thrombomodulin). By activating Factor XIII, covalent bonds are formed that crosslink the fibrin polymers that form from activated monomers.[26] This stabilizes the fibrin network.[citation needed]

The coagulation cascade is maintained in a prothrombotic state by the continued activation of FVIII and FIX to form the tenase complex until it is down-regulated by the anticoagulant pathways.[26]

Cell-based scheme of coagulation

A newer model of coagulation mechanism explains the intricate combination of cellular and biochemical events that occur during the coagulation process in vivo. Along with the procoagulant and anticoagulant plasma proteins, normal physiologic coagulation requires the presence of two cell types for formation of coagulation complexes: cells that express tissue factor (usually extravascular) and platelets.[citation needed]

The coagulation process occurs in two phases. First is the initiation phase, which occurs in tissue-factor-expressing cells. This is followed by the propagation phase, which occurs on activated platelets. The initiation phase, mediated by the tissue factor exposure, proceeds via the classic extrinsic pathway and contributes to about 5% of thrombin production. The amplified production of thrombin occurs via the classic intrinsic pathway in the propagation phase; about 95% of thrombin generated will be during this second phase.[30]

Fibrin clot formation

Fibrinolysis

Eventually, blood clots are reorganized and resorbed by a process termed

plasmin inhibitors.[31]

Role in immune system

The coagulation system overlaps with the

beta-lysine, an amino acid produced by platelets during coagulation, can cause lysis of many Gram-positive bacteria by acting as a cationic detergent.[32] Many acute-phase proteins of inflammation are involved in the coagulation system. In addition, pathogenic bacteria may secrete agents that alter the coagulation system, e.g. coagulase and streptokinase.[citation needed
]

Cofactors

Various substances are required for the proper functioning of the coagulation cascade:

Calcium and phospholipids

microvesicles shed from them.[34] Calcium is also required at other points in the coagulation cascade. Calcium ions play a major role in the regulation of coagulation cascade that is paramount in the maintenance of hemostasis. Other than platelet activation, calcium ions are responsible for complete activation of several coagulation factors, including coagulation Factor XIII.[35]

Vitamin K

dicumarol. These drugs create a deficiency of reduced vitamin K by blocking VKORC, thereby inhibiting maturation of clotting factors. Vitamin K deficiency from other causes (e.g., in malabsorption) or impaired vitamin K metabolism in disease (e.g., in liver failure) lead to the formation of PIVKAs (proteins formed in vitamin K absence), which are partially or totally non-gamma carboxylated, affecting the coagulation factors' ability to bind to phospholipid.[citation needed
]

Regulators

Coagulation with arrows for negative and positive feedback.

Five mechanisms keep platelet activation and the coagulation cascade in check.[citation needed] Abnormalities can lead to an increased tendency toward thrombosis:

Protein C

Protein C is a major physiological anticoagulant. It is a vitamin K-dependent serine protease enzyme that is activated by thrombin into activated protein C (APC). Protein C is activated in a sequence that starts with Protein C and thrombin binding to a cell surface protein thrombomodulin. Thrombomodulin binds these proteins in such a way that it activates Protein C. The activated form, along with protein S and a phospholipid as cofactors, degrades FVa and FVIIIa. Quantitative or qualitative deficiency of either (protein C or protein S) may lead to thrombophilia (a tendency to develop thrombosis). Impaired action of Protein C (activated Protein C resistance), for example by having the "Leiden" variant of Factor V or high levels of FVIII, also may lead to a thrombotic tendency.[citation needed]

Antithrombin

serine protease inhibitor (serpin) that degrades the serine proteases: thrombin, FIXa, FXa, FXIa, and FXIIa. It is constantly active, but its adhesion to these factors is increased by the presence of heparan sulfate (a glycosaminoglycan) or the administration of heparins (different heparinoids increase affinity to FXa, thrombin, or both). Quantitative or qualitative deficiency of antithrombin (inborn or acquired, e.g., in proteinuria) leads to thrombophilia.[citation needed
]

Tissue factor pathway inhibitor (TFPI)

Tissue factor pathway inhibitor (TFPI) limits the action of tissue factor (TF). It also inhibits excessive TF-mediated activation of FVII and FX.[citation needed]

Plasmin

tissue plasminogen activator (t-PA), which is synthesized and secreted by endothelium. Plasmin proteolytically cleaves fibrin into fibrin degradation products that inhibit excessive fibrin formation.[citation needed
]

Prostacyclin

Prostacyclin (PGI2) is released by endothelium and activates platelet Gs protein-linked receptors. This, in turn, activates adenylyl cyclase, which synthesizes cAMP. cAMP inhibits platelet activation by decreasing cytosolic levels of calcium and, by doing so, inhibits the release of granules that would lead to activation of additional platelets and the coagulation cascade.[31]

Medical assessment

Numerous medical tests are used to assess the function of the coagulation system:[36]

The contact activation (intrinsic) pathway is initiated by activation of the "contact factors" of plasma, and can be measured by the activated partial thromboplastin time (aPTT) test.[citation needed]

The tissue factor (extrinsic) pathway is initiated by release of

INR value) to monitor dosing of oral anticoagulants such as warfarin.[citation needed
]

The quantitative and qualitative screening of fibrinogen is measured by the

thrombin clotting time (TCT). Measurement of the exact amount of fibrinogen present in the blood is generally done using the Clauss method
for fibrinogen testing. Many analysers are capable of measuring a "derived fibrinogen" level from the graph of the Prothrombin time clot.

If a coagulation factor is part of the contact activation or tissue factor pathway, a deficiency of that factor will affect only one of the tests: Thus

hemophilia A
, a deficiency of factor VIII, which is part of the contact activation pathway, results in an abnormally prolonged aPTT test but a normal PT test. The exceptions are prothrombin, fibrinogen, and some variants of FX that can be detected only by either aPTT or PT. If an abnormal PT or aPTT is present, additional testing will occur to determine which (if any) factor is present as aberrant concentrations.

Deficiencies of fibrinogen (quantitative or qualitative) will affect all screening tests.

Role in disease

Coagulation defects may cause hemorrhage or thrombosis, and occasionally both, depending on the nature of the defect.[37]

The GP1b-IX receptor complex. This protein receptor complex is found on the surface of platelets, and in conjunction with GPV allows for platelets to adhere to the site of injury. Mutations in the genes associated with the glycoprotein Ib-IX-V complex are characteristic of Bernard–Soulier syndrome.

Platelet disorders

Platelet disorders are either congenital or acquired. Examples of congenital platelet disorders are

dense granules). Most are rare. They predispose to hemorrhage. Von Willebrand disease is due to deficiency or abnormal function of von Willebrand factor, and leads to a similar bleeding pattern; its milder forms are relatively common.[citation needed
]

Decreased platelet numbers (thrombocytopenia) is due to insufficient production (e.g.,

thrombocytosis, which may lead to formation of thromboembolisms.[citation needed
]

Coagulation factor disorders

The best-known coagulation factor disorders are the

hemophilia C (factor XI deficiency, mild bleeding tendency).[medical citation needed
]

Von Willebrand disease (which behaves more like a platelet disorder except in severe cases), is the most common hereditary bleeding disorder and is characterized as being inherited autosomal recessive or dominant. In this disease, there is a defect in von Willebrand factor (vWF), which mediates the binding of glycoprotein Ib (GPIb) to collagen. This binding helps mediate the activation of platelets and formation of primary hemostasis.[medical citation needed]

In acute or chronic liver failure, there is insufficient production of coagulation factors, possibly increasing risk of bleeding during surgery.[39]

Thrombosis is the pathological development of blood clots. These clots may break free and become mobile, forming an embolus or grow to such a size that occludes the vessel in which it developed. An embolism is said to occur when the thrombus (blood clot) becomes a mobile embolus and migrates to another part of the body, interfering with blood circulation and hence impairing organ function downstream of the occlusion. This causes ischemia and often leads to ischemic necrosis of tissue. Most cases of venous thrombosis are due to acquired states (older age, surgery, cancer, immobility) or inherited thrombophilias (e.g., antiphospholipid syndrome, factor V Leiden, and various other genetic deficiencies or variants).[medical citation needed]

Pharmacology

Procoagulants

The use of

glue are used surgically to treat bleeding and to thrombose aneurysms. Hemostatic Powder Spray TC-325 is used to treated gastrointestinal bleeding.[citation needed
]

Coagulation factor concentrates are used to treat

Recombinant activated human factor VII
is increasingly popular in the treatment of major bleeding.

Tranexamic acid and aminocaproic acid inhibit fibrinolysis and lead to a de facto reduced bleeding rate. Before its withdrawal, aprotinin was used in some forms of major surgery to decrease bleeding risk and the need for blood products.

coagulation factor Xa. The drug prevents this protein from activating the coagulation pathway by inhibiting its enzymatic activity
.

Anticoagulants

Anticoagulants and anti-platelet agents (together "antithrombotics") are amongst the most commonly used medications. Anti-platelet agents include aspirin, dipyridamole, ticlopidine, clopidogrel, ticagrelor and prasugrel; the parenteral glycoprotein IIb/IIIa inhibitors are used during angioplasty. Of the anticoagulants, warfarin (and related coumarins) and heparin are the most commonly used. Warfarin affects the vitamin K-dependent clotting factors (II, VII, IX, X) and protein C and protein S, whereas heparin and related compounds increase the action of antithrombin on thrombin and factor Xa. A newer class of drugs, the direct thrombin inhibitors, is under development; some members are already in clinical use (such as lepirudin). Also in clinical use are other small molecular compounds that interfere directly with the enzymatic action of particular coagulation factors (the directly acting oral anticoagulants: dabigatran, rivaroxaban, apixaban, and edoxaban).[41]

History

Initial discoveries

Theories on the coagulation of blood have existed since antiquity. Physiologist

prothrombin".[42][43] Arthus discovered in 1890 that calcium was essential in coagulation.[44][45] Platelets were identified in 1865, and their function was elucidated by Giulio Bizzozero in 1882.[46]

The theory that thrombin is generated by the presence of tissue factor was consolidated by Paul Morawitz in 1905.[47] At this stage, it was known that thrombokinase/thromboplastin (factor III) is released by damaged tissues, reacting with prothrombin (II), which, together with calcium (IV), forms thrombin, which converts fibrinogen into fibrin (I).[48]

Coagulation factors

The remainder of the biochemical factors in the process of coagulation were largely discovered in the 20th century.[citation needed]

A first clue as to the actual complexity of the system of coagulation was the discovery of proaccelerin (initially and later called Factor V) by Paul Owren [no] (1905–1990) in 1947. He also postulated its function to be the generation of accelerin (Factor VI), which later turned out to be the activated form of V (or Va); hence, VI is not now in active use.[48]

Factor VII (also known as serum prothrombin conversion accelerator or proconvertin, precipitated by barium sulfate) was discovered in a young female patient in 1949 and 1951 by different groups.

Factor VIII turned out to be deficient in the clinically recognized but etiologically elusive hemophilia A; it was identified in the 1950s and is alternatively called antihemophilic globulin due to its capability to correct hemophilia A.[48]

Factor IX was discovered in 1952 in a young patient with

AIDS at age 46. An alternative name for the factor is plasma thromboplastin component, given by an independent group in California.[48]

Hageman factor, now known as factor XII, was identified in 1955 in an asymptomatic patient with a prolonged bleeding time named of John Hageman. Factor X, or Stuart-Prower factor, followed, in 1956. This protein was identified in a Ms. Audrey Prower of London, who had a lifelong bleeding tendency. In 1957, an American group identified the same factor in a Mr. Rufus Stuart. Factors XI and XIII were identified in 1953 and 1961, respectively.[48]

The view that the coagulation process is a "cascade" or "waterfall" was enunciated almost simultaneously by MacFarlane[49] in the UK and by Davie and Ratnoff[50] in the US, respectively.

Nomenclature

The usage of

Roman numerals rather than eponyms or systematic names was agreed upon during annual conferences (starting in 1955) of hemostasis experts. In 1962, consensus was achieved on the numbering of factors I–XII.[51] This committee evolved into the present-day International Committee on Thrombosis and Hemostasis (ICTH). Assignment of numerals ceased in 1963 after the naming of Factor XIII. The names Fletcher Factor and Fitzgerald Factor were given to further coagulation-related proteins, namely prekallikrein and high-molecular-weight kininogen, respectively.[48]

Factor VI[citation needed] is unassigned, as accelerin was found to be activated Factor V.

Other species

All mammals have an extremely closely related blood coagulation process, using a combined cellular and serine protease process.[citation needed] In fact, it is possible for any mammalian coagulation factor to "cleave" its equivalent target in any other mammal.[citation needed] The only non-mammalian animal known to use serine proteases for blood coagulation is the horseshoe crab.[52]

See also

References

  1. PMID 16322780
    .
  2. .
  3. from the original on 10 May 2017. Retrieved 8 February 2022.
  4. from the original on 8 February 2022. Retrieved 8 February 2022.
  5. .
  6. ^ "Prothrombin thrombophilia". MedlinePlus. Archived from the original on 12 September 2023. Retrieved 11 September 2023.
  7. ^ a b "Gamma-Glutamyl Carboxylase - an overview | ScienceDirect Topics". ScienceDirect. 9 September 2023. Archived from the original on 9 September 2023. Retrieved 9 September 2023.
  8. PMID 25807083
    .
  9. ^ "Coagulation Cascade: What Is It, Steps, and More | Osmosis". www.osmosis.org. Archived from the original on 8 September 2023. Retrieved 8 September 2023.
  10. ^ "VWF gene: MedlinePlus Genetics". medlineplus.gov. Archived from the original on 11 May 2023. Retrieved 8 September 2023.
  11. PMID 9518049
    .
  12. from the original on 2 August 2022. Retrieved 15 October 2023.
  13. ^ "Chapter 23 - Inflammation and its mediators". Rheumatology (6th edition) | Thromboxane A2 - an overview. Archived from the original on 9 September 2023. Retrieved 15 October 2023 – via ScienceDirect.
  14. from the original on 15 October 2023.
  15. .
  16. .
  17. .
  18. .
  19. ^ "Coagulation Cascade: What Is It, Steps, and More". www.osmosis.org. Archived from the original on 8 September 2023. Retrieved 15 October 2023.
  20. ^
    PMID 28101869
    .
  21. from the original on 12 March 2023, retrieved 15 October 2023
  22. .
  23. .
  24. .
  25. from the original on 8 February 2022. Retrieved 8 February 2022.
  26. ^ .
  27. ^ "Coagulation Factor". Clotbase.bicnirrh.res.in. Archived from the original on 11 December 2016. Retrieved 20 May 2018.
  28. from the original on 8 February 2022. Retrieved 8 February 2022.
  29. ^ .
  30. from the original on 8 February 2022. Retrieved 8 February 2022.
  31. ^ .
  32. ^ Immunology – Chapter One: Innate (non-specific) immunity Archived 21 October 2014 at the Wayback Machine Gene Mayer, Ph.D. Immunology Section of Microbiology and Immunology On-line. University of South Carolina
  33. PMID 25535411
    .
  34. .
  35. .
  36. .
  37. from the original on 8 February 2022. Retrieved 8 February 2022.
  38. ^ "Disseminated Intravascular Coagulation". The Lecturio Medical Concept Library. Archived from the original on 12 July 2021. Retrieved 12 July 2021.
  39. PMID 31778223
    .
  40. .
  41. .
  42. .
  43. ^ Schmidt A. Zur Blutlehre. Leipzig: Vogel, 1892.
  44. ^ Arthus M, Pagès C (1890). "Nouvelle theorie chimique de la coagulation du sang". Arch Physiol Norm Pathol. 5: 739–746.
  45. PMID 14585945
    .
  46. .
  47. .
  48. ^ .
  49. .
  50. .
  51. .
  52. .

Further reading

External links